ATTO

SEC source: 0000886982-26-000522 · wk-form4a_1787953085.xml · nonDerivative · entry 3

GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner

GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner

GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner

Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner

WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner

West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner

WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner

WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 83,565

F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

F2 · ownership.nature: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer.

F3 · ownership.nature: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4.

SEC source: 0000886982-26-000522 · wk-form4a_1787953085.xml · nonDerivative · entry 2

GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner

GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner

GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner

Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner

WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner

West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner

WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner

WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 84,012

F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

F2 · ownership.nature: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer.

F3 · ownership.nature: GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4.

SEC source: 0000886982-26-000522 · wk-form4a_1787953085.xml · nonDerivative · entry 1

GOLDMAN SACHS GROUP INC · CIK 0000886982 · Former 10% Owner

GOLDMAN SACHS & CO. LLC · CIK 0000769993 · Former 10% Owner

GOLDMAN SACHS ASSET MANAGEMENT, L.P. · CIK 0001229262 · Former 10% Owner

Broad Street Principal Investments, L.L.C. · CIK 0001575993 · Former 10% Owner

WSLS OFFSHORE INVESTMENTS, SLP · CIK 0002148330 · Former 10% Owner

West Street Life Sciences I, L.P. · CIK 0001951154 · Former 10% Owner

WSLS EMP OFFSHORE INVESTMENTS, L.P. · CIK 0002148329 · Former 10% Owner

WSLS EMP ONSHORE INVESTMENTS, L.P. · CIK 0002148331 · Former 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 85,000

F1 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

F2 · ownership.nature: These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer.

SEC source: 0001644888-26-000009 · form4a-10092026_121054.xml · derivative · entry 1

Fu Tao · CIK 0001644888 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 538,300

Underlying: Common Stock · 538,300 shares

Expires 2036-08-03

F1 · derivative.exercise_date: 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.

SEC source: 0001654907-26-000009 · form4a-10082026_111058.xml · derivative · entry 1

Chan Steven · CIK 0001654907 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,000

Underlying: Common Stock · 140,000 shares

Expires 2036-08-03

F1 · derivative.exercise_date: 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.

SEC source: 0001242882-26-000004 · form4-08062026_090835.xml · derivative · entry 1

GOLD MITCHELL · CIK 0001242882 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2036-08-03

F1 · derivative.exercise_date: 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.

SEC source: 0001193125-26-338446 · ownership.xml · derivative · entry 1

You Angie · CIK 0001647664 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2036-08-03

F1 · derivative.exercise_date: The options shall fully vest on the earlier of (i) August 4, 2027 and (ii) the next annual meeting of the Company's stockholders, subject to continued service to the Issuer through such date.

SEC source: 0002141590-26-000008 · form4-08062026_090834.xml · derivative · entry 1

Odrowaz Zaneta · CIK 0002141590 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,000

Underlying: Common Stock · 140,000 shares

Expires 2036-08-03

F1 · derivative.exercise_date: 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.

SEC source: 0002142262-26-000006 · form4-08062026_090836.xml · derivative · entry 1

Chen Hubert · CIK 0002142262 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,000

Underlying: Common Stock · 140,000 shares

Expires 2036-08-03

F1 · derivative.exercise_date: 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.

SEC source: 0002141655-26-000008 · form4-08062026_090833.xml · derivative · entry 1

Veiby Petter · CIK 0002141655 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,000

Underlying: Common Stock · 140,000 shares

Expires 2036-08-03

F1 · derivative.exercise_date: 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.

SEC source: 0001193125-26-338430 · ownership.xml · derivative · entry 1

Attovia Therapeutics, Inc. · CIK 0002058707 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,000

Underlying: Common Stock · 140,000 shares

Expires 2036-08-03

F1 · derivative.exercise_date: 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.

SEC source: 0001193125-26-338420 · ownership.xml · derivative · entry 1

Attovia Therapeutics, Inc. · CIK 0002058707 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 538,300

Underlying: Common Stock · 538,300 shares

Expires 2036-08-03

F1 · derivative.exercise_date: 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.